MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-19-0475

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2019

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.

Yu Jiayi, Yan Junya, Guo Qian, Chi Zhihong, Tang Bixia, Zheng Bin, Yu Jinyu, Yin Ting, Cheng Zhiyuan, Wu Xiaowen, Yu Huan, Dai Jie, Sheng Xinan, Si Lu, Cui Chuanliang, Bai Xue, Mao Lili, Lian Bin, Wang Xuan, Yan Xieqia, Li Siming, Zhou Li, Flaherty Keith T, Guo Jun, Kong Yan

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: PD-1 checkpoint blockade immunotherapy induces long and durable response in patients with advanced melanoma. However, only a subset of patients with melanoma benefit from this approach. The mechanism triggering the innate resistance of anti-PD-1 therapy remains unclear.Experimental

Design

Whole-exome sequencing (WES) and RNA sequencing (RNA-Seq) analyses were performed in a training cohort (n = 31) using baseline tumor biopsies of patients with advanced melanoma treated with the anti-PD-1 antibody. Copy-number variations (CNVs) for the genes CDK4, CCND1, and CDKN2A were assayed using a TaqMan copy-number assay in a validation cohort (n = 85). The effect of CDK4/6 inhibitors combined with anti-PD-1 antibody monotherapy was evaluated in PD-1-humanized mouse (C57BL/6-hPD-1) and humanized immune system (HIS) patient-derived xenograft (PDX) models.

RESULTS

WES revealed several significant gene copy-number gains in the patients of no clinical benefit cohort, such as 12q14.1 loci, which harbor CDK4. The association between CDK4 gain and innate resistance to anti-PD-1 therapy was validated in 85 patients with melanoma (P < 0.05). RNA-Seq analysis of CDK4-normal cell lines and CDK4-normal tumors showed altered transcriptional output in TNFα signaling via NF-κB, inflammatory response, and IFNγ response gene set. In addition, CDK4/6 inhibitor (palbociclib) treatment increased PD-L1 protein levels and enhanced efficacy (P < 0.05) in the C57BL/6-hPD-1 melanoma cell and the HIS PDX model.

CONCLUSIONS

In summary, we discovered that genetic aberrations in the CDK4 pathway are associated with innate resistance to anti-PD-1 therapy in patients with advanced melanoma. Moreover, our study provides a strong rationale for combining CDK4/6 inhibitors with anti-PD-1 antibody for the treatment of advanced melanomas.

Для цитирования: Yu Jiayi, Yan Junya, Guo Qian, Chi Zhihong, Tang Bixia, Zheng Bin, Yu Jinyu, Yin Ting, Cheng Zhiyuan, Wu Xiaowen, Yu Huan, Dai Jie, Sheng Xinan, Si Lu, Cui Chuanliang, Bai Xue, Mao Lili, Lian Bin, Wang Xuan, Yan Xieqia, Li Siming, Zhou Li, Flaherty Keith T, Guo Jun, Kong Yan. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. DOI: 10.1158/1078-0432.ccr-19-0475.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.